Citigroup and Wells Fargo have increased their price targets for ResMed following the company's recent fiscal quarterly reporting. This indicates a positive re-evaluation of the company's prospects by these financial institutions, likely driven by strong performance or an improved outlook presented in the report. The adjustments suggest a potentially bullish sentiment for ResMed's stock in the short to medium term.
On October 30, 2026, Citigroup and Wells Fargo both raised their price targets for ResMed, from $240 to $270 and $215 to $250 respectively. These adjustments were made in response to the company's recent fiscal quarterly reporting, suggesting that the report contained positive information that led analysts to revise their outlooks upwards. This development is significant for ResMed as it reflects a more optimistic view from key financial institutions, potentially attracting more investor interest and supporting the stock price in the short term. For traders, this presents an opportunity to consider long positions, though they should also evaluate the underlying quarterly report to understand the drivers behind these target increases and assess any potential risks.